NMN (Nicotinamide Mononucleotide)
NMN is an oral NAD+ precursor that reliably raises blood NAD+ in human trials, but clinical benefits remain modest and endpoint-limited. Yoshino 2021 found a 25% muscle insulin-sensitivity gain in 25 prediabetic postmenopausal women, while 2024-2026 meta-analyses found mostly null glucose and lipid effects in broader adult samples.
NMN (Nicotinamide Mononucleotide) scored 5.8 / 10 (👍 Worth trying) on the BioHarmony scale as a Substance → Exogenous Metabolite.
What It Is
NMN (nicotinamide mononucleotide) is a vitamin B3-derived nucleotide your body can convert into NAD+, a redox cofactor used in energy metabolism, DNA repair, sirtuin signaling, and cellular stress response. In plain English: NMN is one way to refill part of the NAD+ pool that tends to decline with age, metabolic stress, inflammation, and poor lifestyle inputs.
The human evidence is real but narrower than the marketing. Yoshino 2021 found a 25% improvement in clamp-measured muscle insulin sensitivity in 25 prediabetic postmenopausal women at 250 mg/day for 10 weeks. Igarashi 2022 found NAD+ elevation and some muscle-function changes in older men. Liao 2021 found aerobic-capacity marker gains in amateur runners using 300-1200 mg/day alongside training.
But the new meta-analytic layer matters. Chen 2025 and Zhang 2024 both found that oral NMN raises NAD+ without clearly improving broad glucose or lipid outcomes in mostly healthy adults. Zhang 2026 found a small diastolic blood-pressure signal, but the authors framed it as preliminary. So the v1.0 take is tempered: NMN is a legitimate NAD+ precursor, not proven anti-aging medicine.
Terminology
- NAD+: Nicotinamide adenine dinucleotide, oxidized form. Central redox cofactor used in hundreds of enzymatic reactions.
- NADH: Reduced form of NAD+. The NAD+/NADH ratio helps describe cellular redox state.
- NMN: Nicotinamide mononucleotide. A direct NAD+ precursor and the intervention scored here.
- NMNAT: Nicotinamide mononucleotide adenylyltransferase. Enzyme family that converts NMN into NAD+.
- NAMPT: Nicotinamide phosphoribosyltransferase. Rate-limiting enzyme in the NAD+ salvage pathway.
- Slc12a8: Proposed intestinal NMN transporter from a contested transporter paper; the claim remains debated.
- CD38: NAD-consuming enzyme that tends to rise with age and inflammation.
- CD73: Ecto-5-prime-nucleotidase. Enzyme that can cleave extracellular NMN before uptake.
- Sirtuins: NAD+-dependent enzymes involved in metabolic regulation, stress response, and aging biology.
- PARP: Poly(ADP-ribose) polymerase. NAD+-consuming DNA-repair enzyme family.
- NR: Nicotinamide riboside. Another NAD+ precursor, sold commercially as Niagen and other products.
- NAM: Nicotinamide. A vitamin B3 form and NAD+ salvage-pathway substrate.
- TMG: Trimethylglycine, also called betaine. A methyl donor commonly stacked with NAD+ precursors.
- HOMA-IR: Homeostatic Model Assessment of Insulin Resistance. A fasting-glucose and fasting-insulin estimate of insulin resistance.
- HbA1c: Glycated hemoglobin. A roughly 3-month marker of average blood glucose.
- ALT: Alanine aminotransferase. A liver enzyme often used as a liver-stress marker.
- DBP: Diastolic blood pressure. The lower number in a blood-pressure reading.
- NDI: New Dietary Ingredient. FDA notification category for novel supplement ingredients.
- IND: Investigational New Drug application. FDA drug-development filing relevant to NMN's regulatory history.
- WADA: World Anti-Doping Agency. Maintains the athlete prohibited list.
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
View 4 routes and 6 protocols
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Oral capsule | Standard beta-NMN capsule or tablet | 250-2000 mg/day across human trials; 250-1000 mg/day most relevant for consumer protocols | 250-1000 mg/day, usually morning |
| Oral powder | Loose NMN powder mixed with water or swallowed directly | Comparable to oral capsule when dose-matched | 250-1000 mg/day |
| Sublingual tablet | Tablet dissolved under the tongue | No head-to-head RCT validation versus standard oral NMN | 250-500 mg sublingual |
| Liposomal oral | NMN packaged in lipid carriers | No head-to-head RCT validation versus standard oral NMN | 250-500 mg/day |
Protocols
Clinical low-dose metabolic trial Clinical
- Dose
- 250 mg/day oral
- Frequency
- Daily
- Duration
- Minimum 10 weeks
Dose used in Yoshino 2021, the narrow but important insulin-sensitivity trial in prediabetic postmenopausal women.
Standard consumer protocol Mixed
- Dose
- 500 mg/day oral
- Frequency
- Daily, morning
- Duration
- 8-12 week trial, then reassess
Most common community dose. Morning dosing reduces insomnia reports and fits daily supplement routines.
Higher-dose MIB-626 style Mixed
- Dose
- 1000 mg/day oral
- Frequency
- Daily, morning
- Duration
- 14 days to 12 weeks in relevant studies; ongoing use is anecdotal
Pencina 2022 used 1000 mg once daily or twice daily MIB-626 for 14 days. Outcome superiority over 500 mg/day remains unsettled.
Multi-precursor NAD+ stack Anecdotal
- Dose
- 250-500 mg NMN + 300 mg NR + 500 mg TMG
- Frequency
- Daily, morning
- Duration
- Ongoing with periodic reassessment
Nick's preferred approach: multiple NAD+ precursors for pathway diversity plus TMG to support methyl donors.
Longevity cycling Anecdotal
- Dose
- 500 mg/day
- Frequency
- Daily during on-cycle
- Duration
- 12 weeks on, 2-4 weeks off
Community practice, not RCT-validated. Useful for cost control and checking whether NMN is doing anything noticeable.
Exercise-adjacent protocol Mixed
- Dose
- 500 mg after training or in the morning on training days
- Frequency
- Training days or daily
- Duration
- 6-12 weeks
Nearest clinical touchpoint is Liao 2021 in amateur runners; timing strategy itself remains unproven.
Use-Case Specific Dosing
| Use Case | Dose | Notes |
|---|---|---|
How this score is calculated →
Upside contribution: 2.68
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 2.8 | 0.700 | |
| Breadth of Benefits | 15% | 3.0 | 0.450 | |
| Evidence Quality | 25% | 2.8 | 0.700 | |
| Speed of Onset | 10% | 3.0 | 0.300 | |
| Durability | 10% | 1.5 | 0.150 | |
| Bioindividuality Upside | 15% | 2.5 | 0.375 | |
| Total | 2.675 |
Upside Rationale
NMN has its best upside when the user matches NMN to the evidence-backed lane instead of treating it as a broad wellness shortcut. The upside is biochemical reliability: NMN usually raises NAD+ markers. Human benefits are more selective, with better signals in insulin sensitivity, gait speed, liver enzymes, and some physical-function measures than in broad lipid or glucose panels. The most useful anchors are Zhang 2024 and Yoshino 2021, because they explain both the signal and the boundary around that signal. For readers, the so-what is simple: NMN is worth considering when the expected benefit can be observed in a concrete marker, symptom, lab, or performance measure. NMN is weaker when the goal is vague optimization with no baseline and no follow-up.
Efficacy (2.8/5.0). NMN has a credible but modest efficacy profile: Yoshino 2021 showed a 25% insulin-sensitivity improvement in 25 prediabetic postmenopausal women, while broader meta-analyses are less favorable. Pencina 2022 showed 1000 mg once daily or twice daily MIB-626 raised NAD+ and metabolites over 14 days. Igarashi 2022 found gait and muscle-function signals in older men. Liao 2021 found improved aerobic-capacity markers in runners, but not VO2max. The ceiling is the issue: no human RCT has shown mortality reduction, cardiovascular-event reduction, cancer prevention, dementia prevention, or lifespan extension.
Breadth of Benefits (3.0/5.0). NMN touches broad biology because NAD+ touches broad biology. Rajman 2018 lays out how NAD+ supports redox reactions, sirtuins, PARPs, mitochondrial function, and metabolic stress response. Human endpoint evidence is narrower: insulin sensitivity, NAD+ metabolome, gait speed, exercise oxygen-utilization markers, short-term cardiometabolic markers, and small blood-pressure changes. Cardiovascular support is mostly preclinical, including de Picciotto 2016. Longevity, cognition, immune function, libido, fertility, sleep architecture, and skin-beauty claims remain mostly extrapolation.
Evidence Quality (2.8/5.0). NMN has enough RCTs to be taken seriously, but not enough duration or outcome depth to support the stronger longevity claims. The updated evidence base includes Chen 2025, Zhang 2024, Wang 2024, and Zhang 2026. Trials are usually small, short, and focused on biomarkers or intermediate endpoints. There is no Cochrane review, no ADA or Endocrine Society clinical guideline endorsement, and meaningful industry involvement in parts of the ecosystem, especially MIB-626 and branded formulations.
Speed of Onset (3.0/5.0). NMN can move NAD+ markers quickly, but functional changes take weeks. Pencina 2022 measured blood NMN and NAD-metabolome changes over 14 days. Yoshino 2021 needed 10 weeks for insulin-sensitivity outcomes. Igarashi 2022 used 12 weeks in older men. Liao 2021 used 6 weeks with training. This is faster than structural interventions like muscle gain, slower than caffeine, and less subjectively reliable than stimulants or GLP-1 appetite effects.
Durability (1.5/5.0). NMN is a throughput intervention: the effect depends on continued intake. NAD+ elevation fades after supplementation stops, and there is no human evidence that NMN creates durable metabolic reprogramming after discontinuation. That is the biggest upside weakness. Exercise, sauna, cold exposure, sleep regularity, and improved insulin sensitivity from fat loss can create adaptations that persist longer. NMN behaves more like a daily nutrient lever than a skill, habit, or training adaptation. If the capsule stops, the supplemental pressure on NAD+ metabolism stops.
Bioindividuality (2.5/5.0). NMN response likely depends on baseline NAD+ deficit, age, insulin resistance, BMI, activity level, and existing lifestyle quality. Yoshino 2021 studied prediabetic postmenopausal women, not healthy 25-year-old athletes. Igarashi 2022 studied older men. Katayoshi 2023 suggested stronger arterial-stiffness signals in higher-risk subgroups. In practice, older, sedentary, insulin-resistant, or higher-BMI users are more credible candidates. Healthy high performers who already train, sleep well, fast rhythmically, and use heat/cold often see smaller incremental benefit.
Downside contribution: 1.84 (safety risks weighted extra)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety Risk | 30% | 1.5 | 0.450 | |
| Side Effect Profile | 15% | 1.5 | 0.225 | |
| Financial Cost | 5% | 3.0 | 0.150 | |
| Time/Effort Burden | 5% | 1.2 | 0.060 | |
| Opportunity Cost | 5% | 2.5 | 0.125 | |
| Dependency / Withdrawal | 15% | 1.0 | 0.150 | |
| Reversibility | 25% | 1.0 | 0.250 | |
| Total | 1.410 | |||
| Harm subtotal × 1.4 | 1.505 | |||
| Opportunity subtotal × 1.0 | 0.335 | |||
| Combined downside | 1.840 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 0.500 |
Downside Rationale
NMN's main downside is not one isolated risk; it is the mismatch between marketing certainty and the actual evidence base. The downside is cost, regulatory ambiguity, and endpoint disappointment. NMN can move NAD+ labs without producing a clear felt benefit, and long-term high-dose use still has open questions around cancer context, methylation burden, and who actually responds. Igarashi 2022 is the anchor that keeps the safety discussion honest, while Zhang 2024 helps define where the benefits are strongest. The practical move is to treat NMN as a targeted experiment, not a default habit. That means checking contraindications, product quality, dose, medication conflicts, and the opportunity cost of skipping better-supported basics before assigning NMN a permanent role.
Safety Risk (1.5/5.0). NMN looks well tolerated short term, but long-term safety is not closed. Yi 2023 and Pencina 2022 support short-term tolerability across dose ranges, and Yamaguchi 2024 adds longer oral-use data in healthy middle-aged Japanese men. The theoretical cancer caution remains unresolved: NAD+ supports DNA repair, but cancer cells also rely on NAD+ metabolism. That does not prove harm in humans, but active malignancy and PARP inhibitor therapy are sensible avoidance zones. Pregnancy, lactation, and pediatric use remain unstudied.
Side Effect Profile (1.5/5.0). NMN's side-effect profile is thin and usually manageable. Published trials report tolerability broadly comparable to placebo, while community reports cluster around mild nausea, loose stools, stomach discomfort, headache, or insomnia when taken late. Morning dosing solves the sleep issue for most people. Higher-dose or premium formulations do not have clear outcome superiority, so side effects should push users down to 250-500 mg/day or off the compound rather than toward more elaborate delivery systems. No withdrawal syndrome, receptor adaptation, or rebound crash is established.
Financial Cost (3.0/5.0). NMN is expensive for a biomarker-forward supplement. A typical 500 mg/day protocol costs roughly $40-100/month with third-party-tested products, and premium liposomal or sublingual products can exceed $120/month without human RCT proof of superiority. That matters because the alternative NAD+ drivers are cheaper and broader: resistance training, zone 2 cardio, sleep consistency, time-restricted eating, heat, cold, protein adequacy, and metabolic-fat-loss work. For a 20-30% likely non-responder segment among healthy users, the cost score stays meaningfully elevated.
Time / Effort Burden (1.2/5.0). NMN is easy to execute: one capsule or powder dose in the morning. There is no device setup, injection burden, prescription visit, meal timing requirement, or complex titration. The only practical details are choosing a tested brand, keeping the dose consistent for 8-12 weeks, and avoiding late-day dosing if sleep worsens. This is one of NMN's strongest practical advantages. The effort burden rises only when users build sprawling stacks around NMN before proving that the base dose does anything for them.
Opportunity Cost (2.5/5.0). NMN has real opportunity cost because it can distract from higher-confidence NAD+ drivers. Rajman 2018 explains why NAD+ biology is central, but the strongest practical NAD+ interventions are still lifestyle fundamentals. Training, sleep, caloric timing, heat, cold, and metabolic health improve more than NAD+ on a lab panel. They affect cardiovascular fitness, muscle, glucose control, mood, and resilience. NMN stacks cleanly with those, so the score is not severe. But using NMN while ignoring fundamentals is poor sequencing.
Dependency / Withdrawal (1.0/5.0). NMN has no known dependency or withdrawal profile. There is no craving signal, no receptor downregulation model, and no evidence that stopping NMN causes physiology to drop below baseline. The realistic pattern is simple fade: NAD+ markers return toward baseline after supplementation stops, and any subjective benefit fades with them. That is a durability limitation, not dependency. Users can cycle NMN, stop for cost reasons, or run a self-experiment washout without needing medical tapering.
Reversibility (1.0/5.0). NMN is highly reversible. Oral NMN and its metabolites clear without permanent structural changes, and there is no surgery, tissue destruction, gene therapy, or long-lived depot involved. If a user experiences insomnia, gastrointestinal symptoms, or no benefit, stopping is straightforward. The unresolved long-term oncology question is the main reason NMN is not treated as consequence-free, but ordinary discontinuation is clean. This is the low-downside side of the same tradeoff that makes NMN less durable: it does not appear to leave much behind after you stop.
Verdict
NMN is a 5.8/10 fit for older or metabolically strained adults who want an NAD+ precursor trial with measured endpoints, not a reliable anti-aging shortcut for already healthy adults. The cleanest evidence anchors are Zhang 2024, which found NAD levels rose while broad glucose and lipid outcomes stayed limited, and Yoshino 2021, which reported a 25% muscle insulin-sensitivity gain in prediabetic postmenopausal women. Igarashi 2022 adds useful context: found NAD+ elevation and selected physical-function changes in older men. The practical gap is the same one that shows up across the report: mechanism and early outcomes are more convincing than broad real-world certainty. In practice, NMN belongs after the basics, works best when the target is specific, and deserves tracking around benefits, side effects, interactions, and cost before it becomes a standing protocol.
✅ Best for: Adults over 40 with likely NAD+ decline, especially those with insulin resistance, higher BMI, declining physical function, low training volume, or poor lifestyle NAD+ inputs. NMN makes the most sense after the foundations are in place: resistance training, aerobic work, sleep regularity, protein adequacy, metabolic health, sauna or heat, and fasting rhythm. It is also reasonable for self-quantifiers willing to track fasting insulin, HbA1c, blood pressure, subjective energy, and training capacity over an 8-12 week trial.
❌ Avoid if: You have active cancer, are on PARP inhibitor therapy, are pregnant, breastfeeding, under 18, or have complex oncology history without clinician oversight. Avoid NMN if you need guideline-backed diabetes, hypertension, sarcopenia, or cardiovascular care, because no major medical society recommends NMN as treatment. Also skip it if $60-100/month would displace higher-confidence basics, if you expect same-week energy transformation, or if your lifestyle already gives you strong NAD+ support and you are chasing marginal gains.
Use Case Breakdown
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
Metabolic Health: 6.5/10
Score: 6.5/10NMN metabolic health earns 6.5/10 because Yoshino 2021 anchors the most relevant signal. NMN fits metabolic health when raising NAD+ is likely to matter for older, metabolically stressed, or performance-tracking users. The score stays bounded because NAD+ rises more consistently than symptoms, glucose control, lipids, or long-term outcomes. In practice, NMN is most defensible when someone tracks NAD labs where available, glucose, liver enzymes, gait speed, training output, sleep, and energy instead of relying on a vague before-and-after feeling. NMN is less convincing when the basics are ignored or when the use case needs fast, proven clinical treatment. That makes this a measured NAD+ experiment with clear stop rules.
Mitochondrial: 6.0/10
Score: 6.0/10NMN mitochondrial earns 6.0/10 because Igarashi 2022 anchors the most relevant signal. NMN fits mitochondrial when raising NAD+ is likely to matter for older, metabolically stressed, or performance-tracking users. The score stays bounded because NAD+ rises more consistently than symptoms, glucose control, lipids, or long-term outcomes. In practice, NMN is most defensible when someone tracks NAD labs where available, glucose, liver enzymes, gait speed, training output, sleep, and energy instead of relying on a vague before-and-after feeling. NMN is less convincing when the basics are ignored or when the use case needs fast, proven clinical treatment. That makes this a measured NAD+ experiment with clear stop rules.
Energy / Fatigue: 5.5/10
Score: 5.5/10NMN energy earns 5.5/10 because Wang 2024 anchors the most relevant signal. NMN fits energy when raising NAD+ is likely to matter for older, metabolically stressed, or performance-tracking users. The score stays bounded because NAD+ rises more consistently than symptoms, glucose control, lipids, or long-term outcomes. In practice, NMN is most defensible when someone tracks NAD labs where available, glucose, liver enzymes, gait speed, training output, sleep, and energy instead of relying on a vague before-and-after feeling. NMN is less convincing when the basics are ignored or when the use case needs fast, proven clinical treatment. That makes this a measured NAD+ experiment with clear stop rules.
Longevity / Lifespan: 5.5/10
Score: 5.5/10NMN longevity earns 5.5/10 because Zhang 2024 anchors the most relevant signal. NMN fits longevity when raising NAD+ is likely to matter for older, metabolically stressed, or performance-tracking users. The score stays bounded because NAD+ rises more consistently than symptoms, glucose control, lipids, or long-term outcomes. In practice, NMN is most defensible when someone tracks NAD labs where available, glucose, liver enzymes, gait speed, training output, sleep, and energy instead of relying on a vague before-and-after feeling. NMN is less convincing when the basics are ignored or when the use case needs fast, proven clinical treatment. That makes this a measured NAD+ experiment with clear stop rules.
Healthspan: 5.5/10
Score: 5.5/10NMN healthspan earns 5.5/10 because Zhang 2024 anchors the most relevant signal. NMN fits healthspan when raising NAD+ is likely to matter for older, metabolically stressed, or performance-tracking users. The score stays bounded because NAD+ rises more consistently than symptoms, glucose control, lipids, or long-term outcomes. In practice, NMN is most defensible when someone tracks NAD labs where available, glucose, liver enzymes, gait speed, training output, sleep, and energy instead of relying on a vague before-and-after feeling. NMN is less convincing when the basics are ignored or when the use case needs fast, proven clinical treatment. That makes this a measured NAD+ experiment with clear stop rules.
Geriatric / Aging Population: 5.5/10
Score: 5.5/10NMN geriatric earns 5.5/10 because Zhang 2024 anchors the most relevant signal. NMN fits geriatric when raising NAD+ is likely to matter for older, metabolically stressed, or performance-tracking users. The score stays bounded because NAD+ rises more consistently than symptoms, glucose control, lipids, or long-term outcomes. In practice, NMN is most defensible when someone tracks NAD labs where available, glucose, liver enzymes, gait speed, training output, sleep, and energy instead of relying on a vague before-and-after feeling. NMN is less convincing when the basics are ignored or when the use case needs fast, proven clinical treatment. That makes this a measured NAD+ experiment with clear stop rules.
Blood Sugar / Glycemic Control: 5.0/10
Score: 5.0/10NMN blood sugar earns 5.0/10 because Yoshino 2021 anchors the most relevant signal. NMN fits blood sugar when raising NAD+ is likely to matter for older, metabolically stressed, or performance-tracking users. The score stays bounded because NAD+ rises more consistently than symptoms, glucose control, lipids, or long-term outcomes. In practice, NMN is most defensible when someone tracks NAD labs where available, glucose, liver enzymes, gait speed, training output, sleep, and energy instead of relying on a vague before-and-after feeling. NMN is less convincing when the basics are ignored or when the use case needs fast, proven clinical treatment. That makes this a measured NAD+ experiment with clear stop rules.
| Use Case | Score | Summary |
|---|---|---|
| ○ Endurance / Cardio Primary | 4.0 | Liao 2021 found improved aerobic-capacity markers in amateur runners taking 300-1200 mg/day with training, but VO2max itself did not improve significantly. |
| ○ Cardiovascular | 4.0 | Preclinical vascular data from de Picciotto 2016 support vascular-aging mechanisms, and Zhang 2026 found a small diastolic blood-pressure signal. No cardiovascular-event RCT exists. |
| ○ Skin / Beauty | 3.5 | Skin-aging evidence is limited and not central to the verified NMN human base. Current stronger citations are metabolic and NAD+ trials, not dermatology endpoints. |
| ○ Neuroprotection | 3.5 | NAD+ supports neuronal stress-response biology, but NMN neuroprotection is still largely preclinical. Rajman 2018 is mechanistic context, not human neuroprotection proof. |
| ○ Strength / Power | 3.5 | Strength evidence is indirect. Igarashi 2022 found muscle-function changes in older men, but Pencina 2023 did not show strength or fatigability improvement. |
| ○ Recovery / Repair | 3.5 | NAD+ supports PARP-mediated DNA repair, but direct human recovery outcomes are unproven. Treat this as mechanism-adjacent, not a validated recovery tool. |
| ○ Anti-Inflammatory | 3.5 | NAD+ biology intersects with inflammatory pathways, but human NMN anti-inflammatory outcomes are not established. Keep this in the indirect-mechanism bucket. |
| ○ Cellular Senescence | 3.5 | NAD+ supports DNA repair and stress-response biology, but human senescence-marker trials are missing. The score reflects indirect rationale, not direct clearance of senescent cells. |
| ○ Cognition / Focus | 3.0 | Cognitive evidence remains preclinical or indirect. Rajman 2018 summarizes NAD-booster biology, but no completed human NMN cognitive RCT establishes benefit. |
| ○ Sleep Quality | 3.0 | Sleep data are weak. Yamaguchi 2024 studied metabolism and sleep in healthy middle-aged Japanese men, but the practical signal remains mixed, and late dosing can worsen insomnia. |
| ○ Body Composition / Fat Loss | 3.0 | Pencina 2023 found a short-term body-weight difference with MIB-626, but body composition and fat endpoints were not convincingly changed. |
| ○ Muscle Growth / Hypertrophy | 3.0 | No direct hypertrophy evidence supports NMN. Muscle-function data are older-adult and endurance-adjacent, not muscle-growth evidence. |
| ○ Antioxidant / Oxidative Stress | 3.0 | NMN supports redox metabolism rather than acting as a direct antioxidant. Human oxidative-stress outcome evidence remains thin. |
| ○ Telomere / DNA Repair | 3.0 | PARP-mediated DNA repair depends on NAD+, but NMN has no verified human telomere or DNA-damage endpoint trial showing meaningful clinical benefit. |
| ○ Autophagy | 3.0 | The NAD+-sirtuin axis touches autophagy signaling, but no human NMN autophagy-marker trial validates the claim. |
Frequently Asked Questions
How does NMN actually raise NAD+ in the body?
NMN raises NAD+ by serving as an immediate NAD+ precursor that NMNAT enzymes convert into NAD+. Yoshino 2021 and Pencina 2022 show human NAD+ elevation. Intact absorption is still debated: Grozio 2019 proposed Slc12a8 transport, while Schmidt 2019 challenged that model.
NMN versus NR, which NAD+ precursor should I pick?
NMN and NR both raise NAD+, and no head-to-head RCT proves NMN is clinically superior. NR has cleaner historical supplement positioning in the US; NMN has the stronger direct-substrate story. In practice, I prefer precursor diversity rather than pretending one molecule has won. See the NR BioHarmony report for the mirror analysis.
Is oral NMN actually absorbed intact?
Oral NMN clearly raises downstream NAD+ markers, but intact NMN absorption remains unsettled. Grozio 2019 identified Slc12a8 as an NMN transporter, while Schmidt 2019 argued NMN is dephosphorylated before uptake. Clinically, the debate matters less if your target is NAD+ elevation, but it matters for premium-form claims.
What is the right NMN dose, 250, 500, or 1000 mg?
Start with 250-500 mg/day in the morning. 250 mg/day has clinical support from Yoshino 2021, 500 mg/day is the common consumer dose, and 1000 mg/day has MIB-626 pharmacokinetic support from Pencina 2022. Above 1000 mg/day, the evidence-to-cost ratio gets weak fast.
What does FDA's current NMN position mean for US buyers?
FDA docket material indicates beta-NMN is not excluded from the dietary-supplement definition, but that is not FDA approval for safety or effectiveness. The practical shift is regulatory access, not proof of benefit. FDA still does not pre-approve dietary supplements the way it approves drugs, and buyers still need third-party testing and quality control.
Are sublingual and liposomal NMN claims legitimate?
Sublingual and liposomal NMN claims are not backed by head-to-head outcome RCTs. The main human trials used standard oral capsules, tablets, or powder, including Yoshino 2021, Igarashi 2022, and Liao 2021. Unless a premium form proves better NAD+ response in you, standard third-party-tested oral NMN is the sane default.
Is NMN producing clinical benefits or just raising a biomarker?
NMN reliably raises a biomarker, but clinical benefit is still narrow. Yoshino 2021 showed insulin-sensitivity improvement in a specific prediabetic female cohort, and Igarashi 2022 showed gait-speed signal in older men. Newer meta-analyses, including Chen 2025, found mostly null glucose and lipid effects in broader samples.
How should I stack NMN with resveratrol, spermidine, or pterostilbene?
TMG is the most practical add-on because NAD+ turnover increases methylated nicotinamide metabolites. Resveratrol plus NMN is mechanistically popular, but human synergy data are absent. I prefer pairing NMN with lifestyle NAD+ drivers first, then complementary pathways like spermidine for autophagy and urolithin A for mitophagy.
How This Score Could Change
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
| Scenario | Dimensions changed | New score |
|---|---|---|
| Large independent RCT confirms insulin sensitivity and aging biomarker benefits at 12+ months | Evidence 2.8 to 3.8; Efficacy 2.8 to 3.5 | 7.2 / 10 💪 Strong recommend |
| 5-year safety study reports no cancer-incidence signal in long-term NMN users | Safety 1.5 to 1.2; Evidence 2.8 to 3.5 | 6.9 / 10 💪 Strong recommend |
| FDA supplement-status clarity stabilizes US access without efficacy change | Legal only, no dimension shift | 6.2 / 10 👍 Worth trying |
| Cancer case series or oncology safety signal appears in long-term users | Safety 1.5 to 3.0 | 5.1 / 10 👍 Worth trying, weakened |
| Oral bioavailability evidence shows intact NMN absorption is clinically irrelevant versus cheaper precursors | Evidence 2.8 to 2.0; Efficacy 2.8 to 2.3 | 5.1 / 10 👍 Worth trying, weakened |
| Head-to-head NMN versus NR RCT confirms NMN superiority on a hard clinical endpoint | Efficacy 2.8 to 3.5; Evidence 2.8 to 3.3 | 6.8 / 10 💪 Strong recommend |
Key Evidence Sources
- Chen F et al. 2025 - Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults, Current Diabetes Reports. 8 RCTs, 342 participants; no significant pooled benefit on fasting glucose, fasting insulin, HbA1c, HOMA-IR, or lipid profile.
- Zhang J et al. 2024 - Efficacy of oral nicotinamide mononucleotide supplementation on glucose and lipid metabolism for adults, Critical Reviews in Food Science and Nutrition. 12 studies, 513 participants; NAD levels rose, but glucose-control and lipid-profile outcomes were not materially improved.
- Wang JP et al. 2024 - Effects of Nicotinamide Mononucleotide Supplementation on Muscle and Liver Functions Among the Middle-aged and Elderly, Current Pharmaceutical Biotechnology. 9 studies, 412 participants; positive gait-speed and ALT signals, with short duration and endpoint limitations.
- Zhang et al. 2026 - Effects of Nicotinamide Mononucleotide Supplementation on Blood Pressure, Nutrients. 10 RCTs, 349 participants; small diastolic blood-pressure reduction, with preliminary certainty.
- Yoshino M et al. 2021 - Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women, Science. 25 postmenopausal women with prediabetes; 250 mg/day for 10 weeks improved insulin-stimulated glucose disposal by 25%.
- Yamaguchi S et al. 2024 - Safety and efficacy of long-term nicotinamide mononucleotide supplementation on metabolism, sleep, and NAD biosynthesis, Endocrine Journal. Healthy middle-aged Japanese men; long-term oral NMN safety and metabolism/sleep outcomes.
- Pencina KM et al. 2022 - MIB-626 increases circulating NAD and its metabolome in middle-aged and older adults, Journals of Gerontology Series A. 32 adults aged 55-80; 1000 mg once daily or twice daily for 14 days raised blood NAD and metabolites.
- Pencina KM et al. 2023 - NAD Augmentation in Overweight or Obese Middle-Aged and Older Adults, Journal of Clinical Endocrinology and Metabolism. 30 adults; MIB-626 raised NAD metabolites and improved several short-term cardiometabolic markers, with no strength or aerobic-capacity advantage.
- Igarashi M et al. 2022 - Chronic NMN supplementation elevates blood NAD levels and alters muscle function in healthy older men, npj Aging. Older men; 250 mg/day for 12 weeks elevated NAD+ and improved some physical-function measures.
- Liao B et al. 2021 - NMN supplementation enhances aerobic capacity in amateur runners, Journal of the International Society of Sports Nutrition. 48 amateur runners; 300-1200 mg/day with training improved oxygen-utilization markers, not VO2max.
- Yi L et al. 2023 - Safety and efficacy of beta-NMN supplementation in healthy middle-aged adults, GeroScience. Multicenter dose-ranging trial in healthy middle-aged adults; supports short-term safety and NAD+ increase.
- Katayoshi T et al. 2023 - NAD metabolism and arterial stiffness after long-term NMN supplementation, Scientific Reports. 36 healthy adults; 250 mg/day for 12 weeks, with arterial-stiffness signal strongest in higher-risk subgroups.
- Grozio A et al. 2019 - Slc12a8 is a nicotinamide mononucleotide transporter, Nature Metabolism. Proposed direct intestinal NMN transporter; important but contested mechanism paper.
- Schmidt MS, Brenner C 2019 - Absence of evidence that Slc12a8 encodes an NMN transporter, Nature Metabolism. Mechanistic critique of the Slc12a8 intact-transport claim.
- Mills KF et al. 2016 - Long-term NMN administration mitigates age-associated physiological decline in mice, Cell Metabolism. Foundational mouse healthspan paper; useful for mechanism, not human lifespan proof.
- de Picciotto NE et al. 2016 - NMN reverses vascular dysfunction and oxidative stress with aging in mice, Aging Cell. Preclinical vascular-aging support; no direct human cardiovascular-event evidence.
- Rajman L et al. 2018 - Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence, Cell Metabolism. Broad NAD-booster review covering NAD+ biology, animal data, and translational caution.
- FDA 2025 - beta-NMN dietary-supplement position materials surfaced under docket FDA-2023-P-0872. Regulatory signal that beta-NMN is not excluded from dietary-supplement definition; not an efficacy endorsement.
- WADA 2026 - Prohibited List resource page. NMN is not named on the prohibited list; athletes still need contamination and infusion-rule caution.
Holistic Evidence Profile
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: Medium
Citations: Chen 2025, Zhang 2024, Wang 2024, Zhang 2026, Yoshino 2021, Pencina 2022, Pencina 2023, Igarashi 2022, Liao 2021, Yi 2023
Pre-RCT-Era Pharmacology and Use
Confidence: Limited
Citations: Harden 1906 NAD discovery, Goldberger 1915 pellagra work, Elvehjem 1937 niacin identification, Preiss Handler 1958 NAD pathway
Traditional Medicine Systems
Confidence: Low
Holistic Evidence for NMN (Nicotinamide Mononucleotide)
The three lenses converge on NAD+ as important and diverge on isolated NMN as the best way to improve health. Modern trials show blood NAD+ rises and narrow functional signals appear in selected groups. Historical biochemistry supports NAD+ as central to metabolism, not as a supplement guarantee. Traditional food patterns support B-vitamin adequacy without isolated high-dose NMN. Honest synthesis: NMN is a reasonable targeted experiment for older or metabolically strained adults, but lifestyle NAD+ drivers remain the higher-confidence foundation.
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- Truhealth Nad Metabolism Baseline (pre-protocol)
- hs-CRP During | Expected Down
Pulse Dimensions to Watch
- Energy During | Expected Up | Primary
- Drive During | Expected Up | Secondary
- Sleep During | Expected Watch | Tertiary
Subjective Signals (Daily Voice Card)
- Morning Energy Scale 1-5 | During | Expected Up
- Sleep Disruption Scale 1-5 | During | Expected Watch
- Exercise Recovery Scale 1-5 | During | Expected Up
Red Flags: Stop and Consult
- Persistent insomnia or agitation
- New unexplained flushing
Other interventions for Metabolic Health
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–3.6, Caution 3.7–4.7, Neutral 4.8–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–7.9, Top-tier 8.0+.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 1.675 − 0.500 = 1.175
Formula v0.5 maps EV = 0 to score 5.0. Above neutral, 1 EV point equals 1 score point. Below neutral, 1 EV point equals about 0.71 score points, so EV = −7 reaches 0.0 while EV = +5 reaches 10.0. Both sides use the full 5-point half-scale.
Score = 5 + (1.175 / 5) × 5 = 6.2 / 10
